Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02380573 · ClinicalTrials.gov registry record · Phase 2
Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease
A Phase 2 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 2
- Development phase
- 117
- Enrollment target
NCT02380573 is a Phase 2 study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 117 participants.
The verdict
NCT02380573, a Phase 2 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 117 participants
- Enrollment target
Study Summary
A double-blind, placebo-controlled study that aims to investigate the effect of 2-week and 12-week administration of USP methylene blue (MB) on cerebral blood flow, functional connectivity, memory and attention cognitive abilities using fMRI and behavioral measures in healthy aging, mild cognitive impairment (MCI) and mild Alzheimer's disease (AD) subjects.
Interventions
- DRUG Methylene Blue
- DRUG FD&C Blue # 2
- DRUG Phenazopyridine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2015-07 |
| Est. Completion | 2023-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02380573
The ClinicalTrials.gov registry entry for NCT02380573 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Methylene Blue is the first listed.
NCT02380573 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02380573 about?
NCT02380573 is a clinical study titled "Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease". A double-blind, placebo-controlled study that aims to investigate the effect of 2-week and 12-week administration of USP methylene blue (MB) on cerebral blood flow, functional connectivity, memory and attention cognitive abilities using fMRI and behavioral measures in healthy aging, mild cognitive i...
What is the current status of trial NCT02380573?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 117 participants. The study started on 2015-07. Estimated completion is 2023-07.
What interventions are being tested in trial NCT02380573?
The interventions under investigation include: Methylene Blue (DRUG), FD&C Blue # 2 (DRUG), Phenazopyridine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT02380573?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.